Commerzbank Aktiengesellschaft FI Purchases New Position in Moderna, Inc. $MRNA

Commerzbank Aktiengesellschaft FI purchased a new position in Moderna, Inc. (NASDAQ:MRNA) in the first quarter, HoldingsChannel reports. The fund purchased 9,916 shares of the company’s stock, valued at approximately $504,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Moderna by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after acquiring an additional 399,487 shares during the period. Capital World Investors bought a new position in shares of Moderna in the 4th quarter worth approximately $378,299,000. Invesco Ltd. lifted its stake in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the period. Theleme Partners LLP lifted its stake in shares of Moderna by 8.6% in the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after purchasing an additional 626,420 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Moderna by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after purchasing an additional 309,126 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Down 2.7%

NASDAQ:MRNA opened at $58.07 on Thursday. The firm has a market cap of $23.04 billion, a P/E ratio of -7.13 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The firm has a 50-day simple moving average of $58.28 and a two-hundred day simple moving average of $51.57.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the prior year, the company posted ($2.52) EPS. The company’s quarterly revenue was up 260.2% on a year-over-year basis. Analysts predict that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Insider Activity

In related news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 125,088 shares of company stock valued at $6,193,713 in the last quarter. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Morgan Stanley raised their price objective on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group boosted their target price on shares of Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a report on Tuesday. Royal Bank Of Canada upped their target price on shares of Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $40.00.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.